Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan M Fryer

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|July 2, 2022
Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese MicePeng Sun, Christina S Bartlett, Chao Zheng, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 9, 2014
G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanismRyan M Fryer, Khing Jow Ng, Suzanne G Nodop Mazurek, et al.
Plos One|August 30, 2014
CCR1 plays a critical role in modulating pain through hematopoietic and non-hematopoietic cellsNuruddeen D Lewis, Akalushi Muthukumarana, Steven E Fogal, et al.
ACS Medicinal Chemistry Letters|January 25, 2021
Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357Christian Harcken, Johanna Csengery, Michael Turner, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 12, 2022
The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and DiseaseGlenn A Reinhart, Paul C Harrison, Kathleen Lincoln, et al.
Journal of Medicinal Chemistry|October 9, 2007
Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonistsRobert J Altenbach, Huaqing Liu, Patricia N Banfor, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 2011
Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitorsRyan M Fryer, Akalushi Muthukumarana, Rong Rhonda Chen, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Journal of Medicinal Chemistry|March 31, 2006
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonistsPhilip R Kym, Andrew J Souers, Thomas J Campbell, et al.
Pain|January 13, 2009
Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermiaPrisca Honore, Prasant Chandran, Gricelda Hernandez, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|July 2, 2022
Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese MicePeng Sun, Christina S Bartlett, Chao Zheng, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 9, 2014
G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanismRyan M Fryer, Khing Jow Ng, Suzanne G Nodop Mazurek, et al.
Plos One|August 30, 2014
CCR1 plays a critical role in modulating pain through hematopoietic and non-hematopoietic cellsNuruddeen D Lewis, Akalushi Muthukumarana, Steven E Fogal, et al.
ACS Medicinal Chemistry Letters|January 25, 2021
Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357Christian Harcken, Johanna Csengery, Michael Turner, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 12, 2022
The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and DiseaseGlenn A Reinhart, Paul C Harrison, Kathleen Lincoln, et al.
Journal of Medicinal Chemistry|October 9, 2007
Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonistsRobert J Altenbach, Huaqing Liu, Patricia N Banfor, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 2011
Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitorsRyan M Fryer, Akalushi Muthukumarana, Rong Rhonda Chen, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Journal of Medicinal Chemistry|March 31, 2006
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonistsPhilip R Kym, Andrew J Souers, Thomas J Campbell, et al.
Pain|January 13, 2009
Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermiaPrisca Honore, Prasant Chandran, Gricelda Hernandez, et al.
Pageof 5